11. ILD Exacerbation (Acute Exacerbation of Fibrosing ILD / AE-IPF)

Quick Recap

Nests under Acute Respiratory Failure. Covers acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) and the broader acute exacerbation of fibrosing ILD concept, including a critical ARDS-mimic differential.

1. Definition

Acute exacerbation of IPF (AE-IPF) (International Working Group consensus definition): acute, clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality in a patient with underlying IPF, occurring within the last month, with:

• New bilateral ground-glass opacity and/or consolidation superimposed on a background pattern of usual interstitial pneumonia (UIP)
• Not fully explained by cardiac failure or fluid overload

The same concept ('acute exacerbation') is now applied more broadly to other fibrosing ILDs (connective-tissue-disease-associated ILD, hypersensitivity pneumonitis, unclassifiable ILD) presenting with similar acute-on-chronic deterioration.

2. Pathophysiology

Unclear trigger (often none identified — "idiopathic" AE) causes acute diffuse alveolar damage superimposed on chronic fibrotic lung with already-reduced physiologic reserve (low compliance, high dead space, impaired diffusion). Because baseline lung mechanics are already abnormal (restrictive physiology, reduced FVC/DLCO), even modest additional alveolar injury produces disproportionate hypoxemia and mechanical ventilation difficulty compared to a previously normal lung. Identifiable triggers when present: infection (viral most common trigger identified), aspiration, drug toxicity (some chemotherapeutic/biologic agents), pneumothorax, PE, and post-procedural (e.g., post-bronchoscopy, post-surgical lung biopsy) exacerbation — but a specific trigger is often never found, and idiopathic AE-IPF carries a particularly poor prognosis.

Critical concept: AE-IPF is one of the classic "ARDS mimics." It looks identical to ARDS radiographically (bilateral opacities, hypoxemia) but arises on a background of irreversible fibrosis, carries a much higher mortality than typical ARDS, and standard ARDS ventilator strategies may be less effective given the fundamentally different (fibrotic, non-recruitable) lung mechanics.

3. Immediate Stabilization (ABCDE)

Airway/Breathing:

• Supplemental O2/HFNC/NIV as tolerated; escalate per standard hypoxemic respiratory failure approach
• The decision to intubate and mechanically ventilate a patient with AE-IPF should be made explicitly and early, in conversation with the patient/family and pulmonology — mortality with mechanical ventilation in AE-IPF is very high (historically cited >80-90% in-hospital mortality once intubated, though modern series vary), and for many patients without a bridge option (transplant candidacy), intubation may represent a transition toward end-of-life care rather than a bridge to recovery
• If mechanical ventilation is pursued: lung-protective low-tidal-volume strategy is generally still favored (extrapolated from ARDS evidence), though the fibrotic, poorly-recruitable lung may respond differently to PEEP titration than typical ARDS — avoid excessive PEEP that can cause barotrauma in stiff, non-recruitable lung units
• Discuss lung transplant candidacy status early — for patients who are active transplant candidates or plausible candidates, ICU-level support (including ECMO as a bridge to transplant) may be appropriate; for patients who are not transplant candidates, the risk-benefit calculus for invasive mechanical ventilation shifts substantially toward comfort-focused care

Circulation: treat co-existing pulmonary hypertension/cor pulmonale (common in advanced ILD) cautiously — these patients can be preload-sensitive and vasopressor requirements should be managed with awareness of underlying RV dysfunction.

Disability/Exposure: standard assessment; note baseline functional status/oxygen dependence as key context for the goals-of-care conversation.

Checklist:

4. Focused History

Known ILD diagnosis and subtype (IPF vs connective-tissue-disease-ILD vs hypersensitivity pneumonitis vs unclassifiable), baseline severity (home O2 use, recent PFT trend — declining FVC/DLCO predicts worse prognosis and higher AE risk), rate of symptom progression (days, consistent with AE definition), recent infection symptoms, new medications (some antifibrotics, chemotherapeutics, biologics, and amiodarone are associated with drug-induced lung injury that can mimic or trigger AE), aspiration risk factors, recent procedures (bronchoscopy, lung biopsy, surgery), known pulmonary hypertension/cor pulmonale, transplant listing status if applicable, advance directives/prior goals-of-care discussions (often previously discussed given the known progressive nature of the underlying disease).

5. Examination + POCUS

Velcro-like bibasilar crackles (chronic baseline finding, may be diffusely worse), digital clubbing (chronic ILD sign), signs of cor pulmonale/pulmonary hypertension (loud P2, RV heave, peripheral edema), cyanosis, accessory muscle use.

POCUS: diffuse B-lines (non-specific, cannot reliably distinguish AE-IPF from ARDS/cardiogenic edema on ultrasound pattern alone); cardiac views to assess RV function/pulmonary hypertension and to help exclude a primarily cardiogenic explanation for the deterioration.

6. Syndrome Identification

Acute-on-chronic hypoxemic respiratory failure in a patient with known or newly-diagnosed fibrosing ILD, radiographically indistinguishable from ARDS but with distinct prognosis and (often) distinct goals-of-care implications — recognizing the ILD background is the critical cognitive step that changes management framing.

7. Differential Diagnosis

8. Severity Assessment

No single validated ICU severity score specific to AE-IPF; use general ICU scores (SOFA/APACHE II) alongside baseline PFT trend (recent FVC decline is a known predictor of AE risk and mortality) and the GAP index (Gender, Age, Physiology — FVC/DLCO) as a baseline IPF severity/mortality predictor that contextualizes prognosis once an AE occurs.

9. Investigations

Mandatory to actively exclude alternative/treatable causes before accepting "idiopathic AE":

• Labs: CBC, renal/hepatic function, BNP/NT-proBNP (help exclude cardiogenic contribution), procalcitonin/inflammatory markers, blood cultures
• Microbiology: respiratory viral panel (mandatory — viral triggers are the most commonly identified precipitant), sputum/BAL culture if bronchoscopy performed, consider atypical/opportunistic pathogen workup if immunosuppressed
• Imaging: high-resolution CT chest (HRCT) — essential to confirm new bilateral ground-glass/consolidation superimposed on the known/background UIP or other fibrotic pattern, and to exclude pneumothorax, PE (CT angiography protocol), or a clearly alternative process
• Echocardiogram: to assess for cardiogenic contribution and to evaluate RV function/pulmonary hypertension, which affects prognosis and hemodynamic management
• Bronchoscopy with BAL: consider for infection workup, especially in diagnostic uncertainty or immunosuppressed patients — balance yield against procedural risk in a patient with reduced respiratory reserve

10. POCUS

Supportive role only — diffuse B-lines are non-specific and cannot reliably distinguish AE-ILD from ARDS or cardiogenic edema on pattern alone; primary value is in excluding pneumothorax and assessing cardiac/RV function as adjuncts to the workup above.

11. Evidence-Based Management

Supportive care (backbone of management, evidence for disease-modifying acute therapy is weak):

• Oxygen/HFNC/NIV per standard hypoxemic respiratory failure approach; goals-of-care-informed decision on invasive mechanical ventilation (Section 3)
• Lung-protective ventilation principles generally extrapolated and applied if intubated, while recognizing the fibrotic lung's different (less recruitable, lower compliance) mechanics compared to typical ARDS

Corticosteroids: high-dose corticosteroids (e.g., methylprednisolone pulse dosing, similar to regimens used for other severe inflammatory lung processes) are commonly used empirically for AE-IPF despite weak and inconsistent evidence of benefit — rationale is that some component of the acute injury may be inflammatory/treatable even though the overall process is fibrotic; a trial is reasonable in the absence of a clear contraindication (e.g., active untreated infection), with reassessment of benefit within days, similar in spirit to the ARDS steroid approach.

Antifibrotic therapy (nintedanib, pirfenidone): continue home antifibrotic therapy if already prescribed and tolerated; not an acute rescue therapy for the exacerbation itself, but withdrawal is not clearly beneficial either — individualize based on tolerability/GI absorption during critical illness.

Antimicrobials: empiric antimicrobial coverage often given pending infectious workup, given the difficulty definitively excluding infection as a trigger and the poor prognosis if a treatable infection is missed — de-escalate per culture/PCR results.

ECMO: may be considered as a bridge to lung transplant in appropriate candidates; generally not appropriate as a bridge to "recovery" alone in AE-IPF without a transplant pathway, given the underlying fibrotic lung will not recover — this distinction is central to appropriate ECMO candidacy discussions in this population and should involve the transplant/pulmonology team explicitly.

Lung transplantation: the only therapy that changes the trajectory of the underlying disease; urgent transplant evaluation/re-evaluation should be pursued in parallel with acute stabilization for appropriate candidates.

12. Organ Support

Oxygen/ventilatory support per above with explicit goals-of-care framing; ECMO as a transplant bridge in candidates; standard supportive ICU care (nutrition, glycemic control) otherwise.

13. Disease-Specific Therapy

See Section 11 — corticosteroid trial, continuation of antifibrotic therapy, empiric antimicrobials pending workup, and transplant evaluation are the principal disease-specific levers; no therapy has robust RCT-level evidence of mortality benefit specifically for AE-IPF.

14. Consultation Matrix

15. Monitoring Framework

Serial oxygenation trend (P/F ratio), serial HRCT if deteriorating to assess extent of new change, monitor for pneumothorax (increased risk in fibrotic/bullous lung, especially on positive pressure ventilation), watch for steroid-related complications (hyperglycemia, infection risk) if a steroid trial is used, reassess goals of care regularly as trajectory becomes clearer.

16. ICU Bundle Checklist (Daily)

17. Complications

Refractory hypoxemia, barotrauma/pneumothorax (fibrotic/bullous lung is prone to this, especially under positive pressure), ventilator-associated pneumonia, steroid-related complications, progression to death from respiratory failure (the most common outcome for non-transplant-candidates with severe AE-IPF). Prevention: cautious ventilator pressure/volume management, early trigger identification and treatment, proactive goals-of-care planning. Rescue: ECMO as transplant bridge in candidates only.

18. Escalation & De-escalation

Escalate: worsening oxygenation despite supportive care and steroid trial -> reassess transplant candidacy/ECMO bridge eligibility vs shift toward comfort-focused care, per goals of care.

De-escalate: improving oxygenation/imaging (suggests a treatable trigger was identified and responded, e.g., infection or fluid overload rather than pure idiopathic AE) -> wean support, continue disease-directed outpatient management (antifibrotics, transplant workup).

19. ICU Discharge Criteria

Stable or improving oxygen requirement approaching a manageable baseline, underlying trigger (if identified) treated, transplant/pulmonology follow-up arranged, or — if the decision has shifted toward comfort-focused care — transition to an appropriate palliative care setting per patient/family wishes.

20. Documentation & Medicolegal Checklist

21. Key Guidelines

ATS/ERS/JRS/ALAT IPF clinical practice guidelines (diagnosis and management of IPF, including the AE-IPF consensus definition); International Working Group report defining AE-IPF (Collard et al.).

22. Landmark Evidence

• Collard HR et al. Acute exacerbation of idiopathic pulmonary fibrosis: an international working group report. Am J Respir Crit Care Med. 2016;194(3):265-275 — the consensus definition underpinning Section 1.
• Evidence for corticosteroids, immunosuppression, and other pharmacologic interventions in AE-IPF remains low-quality/observational; no large RCT has established a clearly effective disease-modifying acute therapy, which is itself an important evidence gap to communicate to families.
• Studies on ECMO as a bridge to lung transplant in ILD populations support this specific, narrower application rather than general use in AE-IPF.

23. Controversies

The entire acute management strategy is more consensus/expert-opinion-driven than most other respiratory ICU protocols in this library — there is genuine, acknowledged uncertainty about optimal ventilator strategy (standard ARDS lung-protective approach vs an approach tailored to non-recruitable fibrotic lung), the value of corticosteroids (widely used despite weak evidence), and the threshold for offering invasive mechanical ventilation at all outside a transplant pathway. Decisions are highly individualized and should be made collaboratively with pulmonology/transplant teams and, critically, with the patient/family given the poor prognosis without a transplant option.

24. References

1. Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis: an international working group report. Am J Respir Crit Care Med. 2016;194(3):265-275.
2. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68.
3. Agusti AG, Roca J, Gea J, et al. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1991;143(2):219-225.
4. Conditions Mimicking ARDS (including AE-IPF). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 11, ARDS chapter differential diagnosis section).
5. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015;192(2):e3-e19.